Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. They are found in multicellular organisms. In mammals, there are two broad types of stem cells: embryonic stem cells, which are isolated from the inner cell mass of blastocysts, and adult stem cells, which are found in various tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing adult tissues. In a developing embryo, stem cells can differentiate into all the specialized cells—ectoderm, endoderm and mesoderm (see induced pluripotent stem cells)—but also maintain the normal turnover of regenerative organs, such as blood, skin, or intestinal tissues.
There are three known accessible sources of autologous adult stem cells in humans:
- Bone marrow, which requires extraction by harvesting, that is, drilling into bone (typically the femur or iliac crest).
- Adipose tissue (lipid cells), which requires extraction by liposuction.
- Blood, which requires extraction through apheresis, wherein blood is drawn from the donor (similar to a blood donation), and passed through a machine that extracts the stem cells and returns other portions of the blood to the donor.
Stem cells can also be taken from umbilical cord blood just after birth. Of all stem cell types, autologous harvesting involves the least risk. By definition, autologous cells are obtained from one's own body, just as one may bank his or her own blood for elective surgical procedures.
Adult stem cells are frequently used in medical therapies, for example in bone marrow transplantation. Stem cells can now be artificially grown and transformed (differentiated) into specialized cell types with characteristics consistent with cells of various tissues such as muscles or nerves. Embryonic cell lines and autologous embryonic stem cells generated through Somatic-cell nuclear transfer or dedifferentiation have also been proposed as promising candidates for future therapies. Research into stem cells grew out of findings by Ernest A. McCulloch and James E. Till at the University of Toronto in the 1960s.
The classical definition of a stem cell requires that it possess two properties:
- Self-renewal: the ability to go through numerous cycles of cell division while maintaining the undifferentiated state.
- Potency: the capacity to differentiate into specialized cell types. In the strictest sense, this requires stem cells to be either totipotent or pluripotent—to be able to give rise to any mature cell type, although multipotent or unipotent progenitor cells are sometimes referred to as stem cells. Apart from this it is said that stem cell function is regulated in a feed back mechanism.
Two mechanisms exist to ensure that a stem cell population is maintained:
- Obligatory asymmetric replication: a stem cell divides into one mother cell that is identical to the original stem cell, and another daughter cell that is differentiated.
- Stochastic differentiation: when one stem cell develops into two differentiated daughter cells, another stem cell undergoes mitosis and produces two stem cells identical to the original.
Potency specifies the differentiation potential (the potential to differentiate into different cell types) of the stem cell.
- Totipotent (a.k.a. omnipotent) stem cells can differentiate into embryonic and extraembryonic cell types. Such cells can construct a complete, viable organism. These cells are produced from the fusion of an egg and sperm cell. Cells produced by the first few divisions of the fertilized egg are also totipotent.
- Pluripotent stem cells are the descendants of totipotent cells and can differentiate into nearly all cells, i.e. cells derived from any of the three germ layers.
- Multipotent stem cells can differentiate into a number of cell types, but only those of a closely related family of cells.
- Oligopotent stem cells can differentiate into only a few cell types, such as lymphoid or myeloid stem cells.
- Unipotent cells can produce only one cell type, their own, but have the property of self-renewal, which distinguishes them from non-stem cells (e.g. progenitor cells, muscle stem cells).
In practice, stem cells are identified by whether they can regenerate tissue. For example, the defining test for bone marrow or hematopoietic stem cells (HSCs) is the ability to transplant the cells and save an individual without HSCs. This demonstrates that the cells can produce new blood cells over a long term. It should also be possible to isolate stem cells from the transplanted individual, which can themselves be transplanted into another individual without HSCs, demonstrating that the stem cell was able to self-renew.
Properties of stem cells can be illustrated in vitro, using methods such as clonogenic assays, in which single cells are assessed for their ability to differentiate and self-renew. Stem cells can also be isolated by their possession of a distinctive set of cell surface markers. However, in vitro culture conditions can alter the behavior of cells, making it unclear whether the cells will behave in a similar manner in vivo. There is considerable debate as to whether some proposed adult cell populations are truly stem cells.
Embryonic stem (ES) cells are stem cells derived from the inner cell mass of a blastocyst, an early-stage embryo. Human embryos reach the blastocyst stage 4–5 days post fertilization, at which time they consist of 50–150 cells. ES cells are pluripotent and give rise during development to all derivatives of the three primary germ layers: ectoderm, endoderm and mesoderm. In other words, they can develop into each of the more than 200 cell types of the adult body when given sufficient and necessary stimulation for a specific cell type. They do not contribute to the extra-embryonic membranes or the placenta.
Nearly all research to date has made use of mouse embryonic stem cells (mES) or human embryonic stem cells (hES). Both have the essential stem cell characteristics, yet they require very different environments in order to maintain an undifferentiated state. Mouse ES cells are grown on a layer of gelatin as an extracellular matrix (for support) and require the presence of leukemia inhibitory factor (LIF). Human ES cells are grown on a feeder layer of mouse embryonic fibroblasts (MEFs) and require the presence of basic fibroblast growth factor (bFGF or FGF-2). Without optimal culture conditions or genetic manipulation, embryonic stem cells will rapidly differentiate.
A human embryonic stem cell is also defined by the expression of several transcription factors and cell surface proteins. The transcription factors Oct-4, Nanog, and Sox2 form the core regulatory network that ensures the suppression of genes that lead to differentiation and the maintenance of pluripotency. The cell surface antigens most commonly used to identify hES cells are the glycolipids stage specific embryonic antigen 3 and 4 and the keratan sulfate antigens Tra-1-60 and Tra-1-81. The molecular definition of a stem cell includes many more proteins and continues to be a topic of research.
There are currently no approved treatments using embryonic stem cells. The first human trial was approved by the US Food and Drug Administration in January 2009. However, the human trial was not initiated until October 13, 2010 in Atlanta for spinal injury victims. On November 14, 2011 the company conducting the trial announced that it will discontinue further development of its stem cell programs. ES cells, being pluripotent cells, require specific signals for correct differentiation—if injected directly into another body, ES cells will differentiate into many different types of cells, causing a teratoma. Differentiating ES cells into usable cells while avoiding transplant rejection are just a few of the hurdles that embryonic stem cell researchers still face. Many nations currently have moratoria on either ES cell research or the production of new ES cell lines. Because of their combined abilities of unlimited expansion and pluripotency, embryonic stem cells remain a theoretically potential source for regenerative medicine and tissue replacement after injury or disease.
The primitive stem cells located in the organs of fetuses are referred to as fetal stem cells. There are two types of fetal stem cells:
- Fetal proper stem cells come from the tissue of the fetus proper, and are generally obtained after an abortion. These stem cells are not immortal but have a high level of division and are multipotent.
- Extraembryonic fetal stem cells come from extraembryonic membranes, and are generally not distinguished from adult stem cells. These stem cells are acquired after birth, they are not immortal but have a high level of cell division, and are pluripotent.
Adult stem cells, also called somatic (from Greek Σωματικóς, "of the body") stem cells, are stem cells which maintain and repair the tissue in which they are found. They can be found in children, as well as adults.
Pluripotent adult stem cells are rare and generally small in number, but they can be found in umbilical cord blood and other tissues. Bone marrow is a rich source of adult stem cells, which have been used in treating several conditions including spinal cord injury, liver cirrhosis, chronic limb ischemia  and endstage heart failure. The quantity of bone marrow stem cells declines with age and is greater in males than females during reproductive years. Much adult stem cell research to date has aimed to characterize their potency and self-renewal capabilities. In mice, pluripotent stem cells are directly generated from adult fibroblast cultures. However, mice do not live long with stem cell organs.
Most adult stem cells are lineage-restricted (multipotent) and are generally referred to by their tissue origin (mesenchymal stem cell, adipose-derived stem cell, endothelial stem cell, dental pulp stem cell, etc.).
Adult stem cell treatments have been successfully used for many years to treat leukemia and related bone/blood cancers through bone marrow transplants. Adult stem cells are also used in veterinary medicine to treat tendon and ligament injuries in horses.
The use of adult stem cells in research and therapy is not as controversial as the use of embryonic stem cells, because the production of adult stem cells does not require the destruction of an embryo. Additionally, in instances where adult stem cells are obtained from the intended recipient (an autograft), the risk of rejection is essentially non-existent. Consequently, more US government funding is being provided for adult stem cell research.
Multipotent stem cells are also found in amniotic fluid. These stem cells are very active, expand extensively without feeders and are not tumorigenic. Amniotic stem cells are multipotent and can differentiate in cells of adipogenic, osteogenic, myogenic, endothelial, hepatic and also neuronal lines. Amniotic stem cells are a topic of active research.
Use of stem cells from amniotic fluid overcomes the ethical objections to using human embryos as a source of cells. Roman Catholic teaching forbids the use of embryonic stem cells in experimentation; accordingly, the Vatican newspaper "Osservatore Romano" called amniotic stem cells "the future of medicine".
It is possible to collect amniotic stem cells for donors or for autologuous use: the first US amniotic stem cells bank  was opened in 2009 in Medford, MA, by Biocell Center Corporation and collaborates with various hospitals and universities all over the world.
A certain kind of cord blood stem cell (CB-SC) is multipotent and displays embryonic and hematopoietic characteristics. Phenotypic characterization demonstrates that (CB-SCs) display embryonic cell markers (e.g., transcription factors OCT-4 and Nanog, stage-specific embryonic antigen (SSEA)-3, and SSEA-4) and leukocyte common antigen CD45, but that they are negative for blood cell lineage markers (e.g., CD1a, CD3, CD4, CD8, CD11b, CD11c, CD13, CD14, CD19, CD20, CD34, CD41a, CD41b, CD83, CD90, CD105, and CD133).
Additionally, CB-SCs display very low immunogenicity as indicated by expression of a very low level of major histocompatibility complex (MHC) antigens and failure to stimulate the proliferation of allogeneic lymphocytes. They can give rise to three embryonic layer-derived cells in the presence of different inducers.
More specifically, CB-SCs tightly adhere to culture dishes with a large rounded morphology and are resistant to common detaching methods (trypsin/EDTA). CB-SCs are the active agent in stem cell educator therapy, which has therapeutic potential against autoimmune diseases like type 1 diabetes according to studies by Yong Zhao et al.[unreliable medical source?]
These are not adult stem cells, but rather adult cells (e.g. epithelial cells) reprogrammed to give rise to pluripotent capabilities. Using genetic reprogramming with protein transcription factors, pluripotent stem cells equivalent to embryonic stem cells have been derived from human adult skin tissue. Shinya Yamanaka and his colleagues at Kyoto University used the transcription factors Oct3/4, Sox2, c-Myc, and Klf4 in their experiments on cells from human faces. Junying Yu, James Thomson, and their colleagues at the University of Wisconsin–Madison used a different set of factors, Oct4, Sox2, Nanog and Lin28, and carried out their experiments using cells from human foreskin.
As a result of the success of these experiments, Ian Wilmut, who helped create the first cloned animal Dolly the Sheep, has announced that he will abandon somatic cell nuclear transfer as an avenue of research.
Frozen blood samples can be used as a source of induced pluripotent stem cells, opening a new avenue for obtaining the valued cells.
To ensure self-renewal, stem cells undergo two types of cell division (see Stem cell division and differentiation diagram). Symmetric division gives rise to two identical daughter cells both endowed with stem cell properties. Asymmetric division, on the other hand, produces only one stem cell and a progenitor cell with limited self-renewal potential. Progenitors can go through several rounds of cell division before terminally differentiating into a mature cell. It is possible that the molecular distinction between symmetric and asymmetric divisions lies in differential segregation of cell membrane proteins (such as receptors) between the daughter cells.
An alternative theory is that stem cells remain undifferentiated due to environmental cues in their particular niche. Stem cells differentiate when they leave that niche or no longer receive those signals. Studies in Drosophila germarium have identified the signals decapentaplegic and adherens junctions that prevent germarium stem cells from differentiating.
Diseases and conditions where stem cell treatment is being investigated include:
- Rheumatoid arthritis
- Parkinson's disease
- Alzheimer's disease
- Stroke and traumatic brain injury repair
- Learning defects 
- Spinal cord injury repair 
- Heart infarction 
- Anti-cancer 
- Baldness 
- Replace missing teeth 
- Repair hearing 
- Restore vision 
- Amyotrophic lateral sclerosis 
- Crohn's disease 
- Wound healing 
Stem cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is a crude form of stem cell therapy that has been used clinically for many years without controversy. No stem cell therapies other than bone marrow transplant are widely used.
In more recent years, with the ability of scientists to isolate and culture embryonic stem cells, and with scientists' growing ability to create stem cells using somatic cell nuclear transfer and techniques to created induced pluripotent stem cells, controversy has crept in, both related to abortion politics and to human cloning.
Stem cell treatments may require immunosuppression because of a requirement for radiation before the transplant to remove the patient's previous cells, or because the patient's immune system may target the stem cells. One approach to avoid the second possibility is to use stem cells from the same patient who is being treated.
Pluripotency in certain stem cells could also make it difficult to obtain a specific cell type. It is also difficult to obtain the exact cell type needed, because not all cells in a population differentiate uniformly. Undifferentiated cells can create tissues other than desired types.
Some stem cells form tumors after transplantation; pluripotency is linked to tumor formation especially in embryonic stem cells, fetal proper stem cells, induced pluripotent stem cells. Fetal proper stem cells form tumors despite multipotency.
Hepatotoxicity and drug-induced liver injury account for a substantial number of failures of new drugs in development and market withdrawal, highlighting the need for screening assays such as stem cell-derived hepatocyte-like cells, that are capable of detecting toxicity early in the drug development process.
Some of the fundamental patents covering human embryonic stem cells are owned by the Wisconsin Alumni Research Foundation (WARF) - they are patents 5,843,780, 6,200,806, and 7,029,913 invented by James A. Thomson. WARF does not enforce these patents against academic scientists, but does enforce them against companies.
In 2006, a request for the US Patent and Trademark Office (USPTO) to re-examine the three patents was filed by the Public Patent Foundation on behalf of its client, the non-profit patent-watchdog group Consumer Watchdog (formerly the Foundation for Taxpayer and Consumer Rights). In the re-examination process, which involves several rounds of discussion between the USTPO and the parties, the USPTO initially agreed with Consumer Watchdog and rejected all the claims in all three patents, however in response, WARF amended the claims of all three patents to make them more narrow, and in 2008 the USPTO found the amended claims in all three patents to be patentable. The decision on one of the patents (7,029,913) was appealable, while the decisions on the other two were not. Consumer Watchdog appealed the granting of the '913 patent to the USTPO's Board of Patent Appeals and Interferences (BPAI) which granted the appeal, and in 2010 the BPAI decided that the amended claims of the '913 patent were not patentable. However, WARF was able to re-open prosecution of the case and did so, amending the claims of the '913 patent again to make them more narrow, and in January 2013 the amended claims were allowed.
In July 2013, Consumer Watchdog announced that it would appeal the decision to allow the claims of the '913 patent to the US Court of Appeals for the Federal Circuit (CAFC), the federal appeals court that hears patent cases. At a hearing in December 2013, the CAFC raised the question of whether Consumer Watchdog had legal standing to appeal; the case could not proceed until that issue was resolved.
Key research events
||This section is in a list format that may be better presented using prose. (November 2014)|
- 1908: The term "stem cell" was proposed for scientific use by the Russian histologist Alexander Maksimov (1874–1928) at congress of hematologic society in Berlin. It postulated existence of haematopoietic stem cells.
- 1960s: Joseph Altman and Gopal Das present scientific evidence of adult neurogenesis, ongoing stem cell activity in the brain; their reports contradict Cajal's "no new neurons" dogma and are largely ignored.
- 1963: Becker, McCulloch and Till illustrate the presence of self-renewing cells in mouse bone marrow.
- 1968: Bone marrow transplant between two siblings successfully treats SCID.
- 1978: Haematopoietic stem cells are discovered in human cord blood.
- 1981: Mouse embryonic stem cells are derived from the inner cell mass by scientists Martin Evans, Matthew Kaufman, and Gail R. Martin. Gail Martin is attributed for coining the term "Embryonic Stem Cell".
- 1992: Neural stem cells are cultured in vitro as neurospheres.
- 1995: Indian scientist Dr. B.G. Matapurkar pioneers in adult stem-cell research with clinical utilization of research in the body and neo-regeneration of tissues and organs in the body. Received International Patent from US Patent Office (USA) in 2001 (effective from 1995). Clinical utilization in human body also demonstrated and patented in 60 patients (World Journal of Surgery-1999 and 1991).
- 1997: Dr. B.G. Matapurkar's surgical technique on regeneration of tissues and organs is published. Regeneration of fallopian tube and uterus is published.
- 1997: Leukemia is shown to originate from a haematopoietic stem cell, the first direct evidence for cancer stem cells.
- 1998: James Thomson and coworkers derive the first human embryonic stem cell line at the University of Wisconsin–Madison.
- 1998: John Gearhart (Johns Hopkins University) extracted germ cells from fetal gonadal tissue (primordial germ cells) before developing pluripotent stem cell lines from the original extract.
- 2000s: Several reports of adult stem cell plasticity are published.
- 2001: Scientists at Advanced Cell Technology clone first early (four- to six-cell stage) human embryos for the purpose of generating embryonic stem cells.
- 2003: Dr. Songtao Shi of NIH discovers new source of adult stem cells in children's primary teeth.
- 2004–2005: Korean researcher Hwang Woo-Suk claims to have created several human embryonic stem cell lines from unfertilised human oocytes. The lines were later shown to be fabricated.
- 2005: Researchers at Kingston University in England claim to have discovered a third category of stem cell, dubbed cord-blood-derived embryonic-like stem cells (CBEs), derived from umbilical cord blood. The group claims these cells are able to differentiate into more types of tissue than adult stem cells.
- 2005: Researchers at UC Irvine's Reeve-Irvine Research Center are able to partially restore the ability of rats with paralyzed spines to walk through the injection of human neural stem cells.
- April 2006 Scientists at the University of Illinois at Chicago identified novel stem cells from the umbilical cord blood with embryonic and hematopoietic characteristics.
- August 2006: Mouse Induced pluripotent stem cells: the journal Cell publishes Kazutoshi Takahashi and Shinya Yamanaka.
- November 2006: Yong Zhao et al. revealed the immune regulation of T lymphocytes by Cord Blood-Derived Multipotent Stem Cells (CB-SCs).
- October 2006: Scientists at Newcastle University in England create the first ever artificial liver cells using umbilical cord blood stem cells.
- January 2007: Scientists at Wake Forest University led by Dr. Anthony Atala and Harvard University report discovery of a new type of stem cell in amniotic fluid. This may potentially provide an alternative to embryonic stem cells for use in research and therapy.
- June 2007: Research reported by three different groups shows that normal skin cells can be reprogrammed to an embryonic state in mice. In the same month, scientist Shoukhrat Mitalipov reports the first successful creation of a primate stem cell line through somatic cell nuclear transfer
- October 2007: Mario Capecchi, Martin Evans, and Oliver Smithies win the 2007 Nobel Prize for Physiology or Medicine for their work on embryonic stem cells from mice using gene targeting strategies producing genetically engineered mice (known as knockout mice) for gene research.
- November 2007: Human induced pluripotent stem cells: Two similar papers released by their respective journals prior to formal publication: in Cell by Kazutoshi Takahashi and Shinya Yamanaka, "Induction of pluripotent stem cells from adult human fibroblasts by defined factors", and in Science by Junying Yu, et al., from the research group of James Thomson, "Induced pluripotent stem cell lines derived from human somatic cells": pluripotent stem cells generated from mature human fibroblasts. It is possible now to produce a stem cell from almost any other human cell instead of using embryos as needed previously, albeit the risk of tumorigenesis due to c-myc and retroviral gene transfer remains to be determined.
- January 2008: Robert Lanza and colleagues at Advanced Cell Technology and UCSF create the first human embryonic stem cells without destruction of the embryo
- January 2008: Development of human cloned blastocysts following somatic cell nuclear transfer with adult fibroblasts
- February 2008: Generation of pluripotent stem cells from adult mouse liver and stomach: these iPS cells seem to be more similar to embryonic stem cells than the previously developed iPS cells and not tumorigenic, moreover genes that are required for iPS cells do not need to be inserted into specific sites, which encourages the development of non-viral reprogramming techniques.
- March 2008-The first published study of successful cartilage regeneration in the human knee using autologous adult mesenchymal stem cells is published by clinicians from Regenerative Sciences
- October 2008: Sabine Conrad and colleagues at Tübingen, Germany generate pluripotent stem cells from spermatogonial cells of adult human testis by culturing the cells in vitro under leukemia inhibitory factor (LIF) supplementation.
- 30 October 2008: Embryonic-like stem cells from a single human hair.
- January 2009: Yong Zhao and colleagues confirmed the reversal of autoimmune-caused type 1 diabetes by Cord Blood-Derived Multipotent Stem Cells (CB-SCs) in an animal experiment.
- 1 March 2009: Andras Nagy, Keisuke Kaji, et al. discover a way to produce embryonic-like stem cells from normal adult cells by using a novel "wrapping" procedure to deliver specific genes to adult cells to reprogram them into stem cells without the risks of using a virus to make the change. The use of electroporation is said to allow for the temporary insertion of genes into the cell.
- 28 May 2009 Kim et al. announced that they had devised a way to manipulate skin cells to create patient specific "induced pluripotent stem cells" (iPS), claiming it to be the 'ultimate stem cell solution'.
- 11 October 2010 First trial of embryonic stem cells in humans.
- 25 October 2010: Ishikawa et al. write in the Journal of Experimental Medicine that research shows that transplanted cells that contain their new host's nuclear DNA could still be rejected by the invidual's immune system due to foreign mitochondrial DNA. Tissues made from a person's stem cells could therefore be rejected, because mitochondrial genomes tend to accumulate mutations.
- 2011: Israeli scientist Inbar Friedrich Ben-Nun led a team which produced the first stem cells from endangered species, a breakthrough that could save animals in danger of extinction.
- January 2012: The human clinical trial of treating type 1 diabetes with lymphocyte modification using Cord Blood-Derived Multipotent Stem Cells (CB-SCs) achieved an improvement of C-peptide levels, reduced the median glycated hemoglobin A1C (HbA1c) values, and decreased the median daily dose of insulin in both human patient groups with and without residual beta cell function. Yong Zhao's Stem Cell Educator Therapy appears "so simple and so safe"
- October 2012: Positions of nucleosomes in mouse embryonic stem cells and the changes in their positions during differentiation to neural progenitor cells and embryonic fibroblasts are determined with single-nucleotide resolution.
- 2012: Katsuhiko Hayashi used mouse skin cells to create stem cells and then used these stem cells to create mouse eggs. These eggs were then fertilized and produced healthy baby offspring. These latter mice were able to have their own babies.
- 2013: First time lab grown meat made from muscle stem-cells has been cooked and tasted.
- 2013: First time mice adult cells were reprogrammed into stem cells in vivo.
- 2013: Scientists at Scotland's Heriot-Watt University developed a 3D printer that can produce clusters of living human embryonic stem cells, potentially allowing complete organs to be printed on demand in the future.
- 2014: Adult mouse cells reprogrammed to pluripotent stem cells using stimulus-triggered acquisition of pluripotency (STAP); a process which involved bathing blood cells in an acid bath (pH 5.7) for 30minutes at 37 °C. A little over a month after the publication of these findings, errors were discovered and the quality of the research has been widely questioned. Further irregularities regarding the mice used have emerged as recently as June 2014.
- Cell bank
- Human genome
- Partial cloning
- Plant stem cell
- Stem cell controversy
- Stem cell marker
- Tuch BE (2006). "Stem cells—a clinical update". Australian Family Physician 35 (9): 719–21. PMID 16969445.
- Becker AJ, McCulloch EA, Till JE (1963). "Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells". Nature 197 (4866): 452–4. Bibcode:1963Natur.197..452B. doi:10.1038/197452a0. PMID 13970094.
- Siminovitch L, Mcculloch EA, Till JE (1963). "The distribution of colony-forming cells among spleen colonies". Journal of Cellular and Comparative Physiology 62 (3): 327–36. doi:10.1002/jcp.1030620313. PMID 14086156.
- Schöler, Hans R. (2007). "The Potential of Stem Cells: An Inventory". In Nikolaus Knoepffler, Dagmar Schipanski, and Stefan Lorenz Sorgner. Humanbiotechnology as Social Challenge. Ashgate Publishing. p. 28. ISBN 978-0-7546-5755-2.
- Mitalipov S, Wolf D (2009). "Totipotency, pluripotency and nuclear reprogramming". Adv. Biochem. Eng. Biotechnol. Advances in Biochemical Engineering/Biotechnology 114: 185–99. Bibcode:2009esc..book..185M. doi:10.1007/10_2008_45. ISBN 978-3-540-88805-5. PMC 2752493. PMID 19343304.
- Ulloa-Montoya F, Verfaillie CM, Hu WS (2005). "Culture systems for pluripotent stem cells". J Biosci Bioeng. 100 (1): 12–27. doi:10.1263/jbb.100.12. PMID 16233846.
- Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luriá EA, Ruadkow IA (1974). "Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method". Experimental Hematology 2 (2): 83–92. ISSN 0301-472X. PMID 4455512.
- Friedenstein AJ, Gorskaja JF, Kulagina NN (1976). "Fibroblast precursors in normal and irradiated mouse hematopoietic organs". Experimental Hematology 4 (5): 267–74. PMID 976387.
- Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM (1998). "Blastocysts Embryonic Stem Cell Lines Derived from Human". Science 282 (5391): 1145–1147. Bibcode:1998Sci...282.1145T. doi:10.1126/science.282.5391.1145. PMID 9804556.
- "Culture of Human Embryonic Stem Cells (hESC)". National Institutes of Health. Archived from the original on 2010-01-06. Retrieved 2010-03-07.
- Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A (2003). "Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells". Cell 113 (5): 643–55. doi:10.1016/S0092-8674(03)00392-1. PMID 12787505.
- Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK, Melton DA, Jaenisch R, Young RA (2005). "Core transcriptional regulatory circuitry in human embryonic stem cells". Cell 122 (6): 947–56. doi:10.1016/j.cell.2005.08.020. PMC 3006442. PMID 16153702.
- Adewumi O, Aflatoonian B, Ahrlund-Richter L, Amit M, Andrews PW, Beighton G, Bello PA, Benvenisty N, Berry LS, Bevan S, Blum B, Brooking J, Chen KG, Choo AB, Churchill GA, Corbel M, Damjanov I, Draper JS, Dvorak P, Emanuelsson K, Fleck RA, Ford A, Gertow K, Gertsenstein M, Gokhale PJ, Hamilton RS, Hampl A, Healy LE, Hovatta O, Hyllner J, Imreh MP, Itskovitz-Eldor J, Jackson J, Johnson JL, Jones M, Kee K, King BL, Knowles BB, Lako M, Lebrin F, Mallon BS, Manning D, Mayshar Y, McKay RD, Michalska AE, Mikkola M, Mileikovsky M, Minger SL, Moore HD, Mummery CL, Nagy A, Nakatsuji N, O'Brien CM, Oh SK, Olsson C, Otonkoski T, Park KY, Passier R, Patel H, Patel M, Pedersen R, Pera MF, Piekarczyk MS, Pera RA, Reubinoff BE, Robins AJ, Rossant J, Rugg-Gunn P, Schulz TC, Semb H, Sherrer ES, Siemen H, Stacey GN, Stojkovic M, Suemori H, Szatkiewicz J, Turetsky T, Tuuri T, van den Brink S, Vintersten K, Vuoristo S, Ward D, Weaver TA, Young LA, Zhang W (2007). "Characterization of human embryonic stem cell lines by the International Stem Cell Initiative". Nat. Biotechnol 25 (7): 803–16. doi:10.1038/nbt1318. PMID 17572666.
- Ron Winslow (2009). "First Embryonic Stem-Cell Trial Gets Approval from the FDA". The Wall Street Journal. 23. January 2009.
- "Embryonic Stem Cell Therapy At Risk? Geron Ends Clinical Trial". ScienceDebate.com. Retrieved 2011-12-11.
- Wu DC, Boyd AS, Wood KJ (2007). "Embryonic stem cell transplantation: potential applicability in cell replacement therapy and regenerative medicine". Front Biosci 12 (8–12): 4525–35. doi:10.2741/2407. PMID 17485394.
- Ariff Bongso; Eng Hin Lee, ed. (2005). "Stem cells: their definition, classification and sources". Stem Cells: From Benchtop to Bedside. World Scientific. p. 5. ISBN 981-256-126-9. OCLC 443407924.
- Moore, K.L., T.V.N. Persaud, and A.G. Torchia. Before We Are Born: Essentials of Embryology and Birth Defects. Philadelphia, PA: Saunders, Elsevier. 2013. Print
- "Stem Cells" Mayo Clinic. Mayo foundation for medical education and research n.d Web. March 23, 2013
- Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM (2002). "Pluripotency of mesenchymal stem cells derived from adult marrow". Nature 418 (6893): 41–9. doi:10.1038/nature00870. PMID 12077603.
- Ratajczak MZ, Machalinski B, Wojakowski W, Ratajczak J, Kucia M (2007). "A hypothesis for an embryonic origin of pluripotent Oct-4(+) stem cells in adult bone marrow and other tissues". Leukemia 21 (5): 860–7. doi:10.1038/sj.leu.2404630. PMID 17344915.
- Narasipura SD, Wojciechowski JC, Charles N, Liesveld JL, King MR (2008). "P-Selectin coated microtube for enrichment of CD34+ hematopoietic stem and progenitor cells from human bone marrow". Clin Chem 54 (1): 77–85. doi:10.1373/clinchem.2007.089896. PMID 18024531.
- William JB, Prabakaran R , Ayyappan S, Puskhinraj H, Rao D, Manjunath SR, Thamaraikannan P, Dedeepiya VD, Kuroda S, Yoshioka H, Mori Y, Preethy SK, Abraham SJK (2011). "Functional Recovery of Spinal Cord Injury Following Application of Intralesional Bone Marrow Mononuclear Cells Embedded in Polymer Scaffold – Two Year Follow-up in a Canine". Journal of Stem Cell Research & Therapy 1 (3). doi:10.4172/2157-7633.1000110.
- Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, Yokoyama Y, Uchida K, Yamasaki T, Fujii Y, Okita K, Sakaida I (2006). "Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy". Stem Cells 24 (10): 2292–8. doi:10.1634/stemcells.2005-0542. PMID 16778155.
- Subrammaniyan R, Amalorpavanathan J, Shankar R, et al. (September 2011). "Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as a result of diabetes: our experience". Cytotherapy 13 (8): 993–9. doi:10.3109/14653249.2011.579961. PMID 21671823.
- Madhusankar N. "Use of Bone Marrow derived Stem Cells in Patients with Cardiovascular Disorders". Journal of Stem Cells and Regenerative Medicine.
- Dedeepiya VD, Rao YY, Jayakrishnan GA, Parthiban JK, Baskar S, Manjunath SR, Senthilkumar R, Abraham SJ (2012). "Index of CD34+ Cells and Mononuclear Cells in the Bone Marrow of Spinal Cord Injury Patients of Different Age Groups: A Comparative Analysis". Bone Marrow Res 2012: 787414. doi:10.1155/2012/787414. PMC 3398573. PMID 22830032.
- Gardner RL (2002). "Stem cells: potency, plasticity and public perception". Journal of Anatomy 200 (3): 277–82. doi:10.1046/j.1469-7580.2002.00029.x. PMC 1570679. PMID 12033732.
- Takahashi K, Yamanaka S (2006). "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors". Cell 126 (4): 663–76. doi:10.1016/j.cell.2006.07.024. PMID 16904174.
- Barrilleaux B, Phinney DG, Prockop DJ, O'Connor KC (2006). "Review: ex vivo engineering of living tissues with adult stem cells". Tissue Eng 12 (11): 3007–19. doi:10.1089/ten.2006.12.3007. PMID 17518617.
- Gimble JM, Katz AJ, Bunnell BA (2007). "Adipose-derived stem cells for regenerative medicine". Circ Res 100 (9): 1249–60. doi:10.1161/01.RES.0000265074.83288.09. PMID 17495232.
- "Bone Marrow Transplant".
- Kane, Ed (2008-05-01). "Stem-cell therapy shows promise for horse soft-tissue injury, disease". DVM Newsmagazine. Retrieved 2008-06-12.
- "Stem Cell FAQ". US Department of Health and Human Services. 2004-07-14. Archived from the original on 2009-01-09.
- De Coppi P, Bartsch G, Siddiqui MM, Xu T, Santos CC, Perin L, Mostoslavsky G, Serre AC, Snyder EY, Yoo JJ, Furth ME, Soker S, Atala A (2007). "Isolation of amniotic stem cell lines with potential for therapy". Nature Biotechnology 25 (5): 100–106. doi:10.1038/nbt1274. PMID 17206138.
- "Vatican newspaper calls new stem cell source 'future of medicine' :: Catholic News Agency (CNA)". Catholic News Agency. 2010-02-03. Retrieved 2010-03-14.
- "European Biotech Company Biocell Center Opens First U.S. Facility for Preservation of Amniotic Stem Cells in Medford, Massachusetts". Reuters. 2009-10-22. Retrieved 2010-03-14.
- "Europe's Biocell Center opens Medford office – Daily Business Update". The Boston Globe. 2009-10-22. Retrieved 2010-03-14.
- "The Ticker". BostonHerald.com. 2009-10-22. Retrieved 2010-03-14.
- "Biocell Center opens amniotic stem cell bank in Medford". Mass High Tech Business News. 2009-10-23. Retrieved 2012-08-26.
- "News » World’s First Amniotic Stem Cell Bank Opens In Medford". wbur.org. Retrieved 2010-03-14.
- "Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique... – MEDFORD, Mass., March 8 /PRNewswire/". Massachusetts: Prnewswire.com. Retrieved 2010-03-14.
- Zhao Y, Wang H, Mazzone T (Aug 1, 2006). "Identification of stem cells from human umbilical cord blood with embryonic and hematopoietic characteristics". Exp Cell Res 312 (13): 2454–2464. doi:10.1016/j.yexcr.2006.04.008. PMID 16716296.
- Zhao Y, Lin B, Darflinger R, Zhang Y, Holterman MJ, Skidgel RA (January 19, 2009). "Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice". PLoS ONE 4 (1): e4226. Bibcode:2009PLoSO...4.4226Z. doi:10.1371/journal.pone.0004226. PMC 2627485. PMID 19156219.
- Zhao Y, Huang Z, Qi M, Lazzarini P, Mazzone T (2007). "Immune regulation of T lymphocyte by a newly characterized human umbilical cord blood stem cell". Immunol Lett 108 (1): 78–87. doi:10.1016/j.imlet.2006.10.007. PMID 17161871.
- Zhao Y, Mazzone T (2010). "Human cord blood stem cells and the journey to a cure for type 1 diabetes". Autoimmun Rev 10 (2): 103–107. doi:10.1016/j.autrev.2010.08.011. PMID 20728583.
- Zhao Y, Lin B, Dingeldein M, Guo C, Hwang D, Holterman MJ (May 2010). "New type of human blood stem cell: a double-edged sword for the treatment of type 1 diabetes". Transl Res. 155 (5): 211–216. doi:10.1016/j.trsl.2010.01.003. PMID 20403575.
- Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Yin Z, Li H, Zhang Y, Diao Y, Li Y, Chen Y, Sun X, Fisk MB, Skidgel R, Holterman M, Prabhakar B, Mazzone T (Jan 10, 2012). "Reversal of type 1 diabetes via islet ß cell regeneration following immune modulation by cord blood-derived multipotent stem cells". BMC Medicine 2012 10: 1–11. doi:10.1186/1741-7015-10-3. PMC 3322343. PMID 22233865.
- Zhao Y (Oct 2012). "Stem cell educator therapy and induction of immune balance". Curr Diab Rep 12 (5): 517–523. doi:10.1007/s11892-012-0308-1. PMID 22833322.
- "Making human embryonic stem cells". The Economist. 2007-11-22.
- Brand, Madeleine; Palca, Joe and Cohen, Alex (2007-11-20). "Skin Cells Can Become Embryonic Stem Cells". National Public Radio.
- "Breakthrough Set to Radically Change Stem Cell Debate". News Hour with Jim Lehrer. 2007-11-20.
- "His inspiration comes from the research by Prof Shinya Yamanaka at Kyoto University, which suggests a way to create human embryo stem cells without the need for human eggs, which are in extremely short supply, and without the need to create and destroy human cloned embryos, which is bitterly opposed by the pro life movement."Highfield, Roger (2007-11-16). "Dolly creator Prof Ian Wilmut shuns cloning". London: The Telegraph.
- Frozen blood a source of stem cells, study finds. newsdaily.com (2010-07-01)
- Beckmann J, Scheitza S, Wernet P, Fischer JC, Giebel B (2007). "Asymmetric cell division within the human hematopoietic stem and progenitor cell compartment: identification of asymmetrically segregating proteins". Blood 109 (12): 5494–501. doi:10.1182/blood-2006-11-055921. PMID 17332245.
- Xie T, Spradling AC (1998). "decapentaplegic is essential for the maintenance and division of germline stem cells in the Drosophila ovary". Cell 94 (2): 251–60. doi:10.1016/S0092-8674(00)81424-5. PMID 9695953.
- Song X, Zhu CH, Doan C, Xie T (2002). "Germline stem cells anchored by adherens junctions in the Drosophila ovary niches". Science 296 (5574): 1855–7. Bibcode:2002Sci...296.1855S. doi:10.1126/science.1069871. PMID 12052957.
- Stem Cell Basics: What are the potential uses of human stem cells and the obstacles that must be overcome before these potential uses will be realized?. In Stem Cell Information World Wide Web site. Bethesda, MD: National Institutes of Health, U.S. Department of Health and Human Services, 2009. cited Sunday, April 26, 2009
- Steinberg, Douglas (November 2000) Stem Cells Tapped to Replenish Organs thescientist.com
- ISRAEL21c: Israeli scientists reverse brain birth defects using stem cells December 25, 2008. (Researchers from the Hebrew University of Jerusalem-Hadassah Medical led by Prof. Joseph Yanai)
- Kang KS, Kim SW, Oh YH, Yu JW, Kim KY, Park HK, Song CH, Han H (2005). "A 37-year-old spinal cord-injured female patient, transplanted of multipotent stem cells from human UC blood, with improved sensory perception and mobility, both functionally and morphologically: a case study". Cytotherapy 7 (4): 368–73. doi:10.1080/14653240500238160. PMID 16162459.
- Strauer BE, Schannwell CM, Brehm M (2009). "Therapeutic potentials of stem cells in cardiac diseases". Minerva Cardioangiol 57 (2): 249–67. PMID 19274033.
- Stem Cells Tapped to Replenish Organs thescientist.com, Nov 2000. By Douglas Steinberg
- Hair Cloning Nears Reality as Baldness Cure WebMD November 2004
- Yen AH, Sharpe PT (2008). "Stem cells and tooth tissue engineering". Cell Tissue Res. 331 (1): 359–72. doi:10.1007/s00441-007-0467-6. PMID 17938970.
- Gene therapy is first deafness 'cure' – health – 14 February 2005 – New Scientist
- BBC NEWS | England | Southern Counties | Stem cells used to restore vision
- Vastag B (2001). "Stem Cells Step Closer to the Clinic: Paralysis Partially Reversed in Rats with ALS-like Disease". JAMA: the Journal of the American Medical Association 285 (13): 1691–1693. doi:10.1001/jama.285.13.1691. PMID 11277806.
- Anderson, Querida (2008-06-15). "Osiris Trumpets Its Adult Stem Cell Product". Genetic Engineering & Biotechnology News (Mary Ann Liebert, Inc.). p. 13. Retrieved 2008-07-06.
(subtitle) Procymal is being developed in many indications, GvHD being the most advanced
- Gurtner GC, Callaghan MJ, Longaker MT (2007). "Progress and potential for regenerative medicine". Annu. Rev. Med. 58: 299–312. doi:10.1146/annurev.med.58.082405.095329. PMID 17076602. Bone marrow transplantation is, as of 2009, the only established use of stem cells.
- Ian Murnaghan for Explore Stem Cells. Updated: 16 December 2013 Why Perform a Stem Cell Transplant?
- Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation In National Cancer Institute Fact Sheet web site. Bethesda, MD: National Institutes of Health, U.S. Department of Health and Human Services, 2010. Cited August 24, 2010
- Bubela T, Li MD, Hafez M, Bieber M, Atkins H (2012). "Is belief larger than fact: expectations, optimism and reality for translational stem cell research". BMC Med 10: 133. doi:10.1186/1741-7015-10-133. PMC 3520764. PMID 23131007.
- Moore, Keith L., T.V.N. Persaud, and Mark G. Torchia. Before We Are Born: Essentials of Embryology and Birth Defects. Philadelphia, PA: Saunders, Elsevier. 2013 Print.
- Greenhough S, Hay DC. (2012). "Stem Cell-Based Toxicity Screening: Recent Advances in Hepatocyte Generation". Pharm Med 26 (2): 85–89. doi:10.1007/BF03256896.
- Regalado, Antonio, David P. Hamilton (July 2006). "How a University's Patents May Limit Stem-Cell Researcher." The Wall Street Journal. Retrieved on July 24, 2006.
- Stephen Jenei for Patent Baristas, April 3, 2007 WARF Stem Cell Patents Knocked Down in Round One
- Stephen Jenei for Patent Baristas, March 3, 2008 Ding! WARF Wins Round 2 As Stem Cell Patent Upheld
- Constance Holden for Science Now. March 12, 2008 WARF Goes 3 for 3 on Patents
- Stephen G. Kunin for Patents Post Grant. May 10, 2010 BPAI Rejects WARF Stem Cell Patent Claims in Inter Partes Reexamination Appeal
- United States Patent And Trademark Office. Board Of Patent Appeals and Interferences. The Foundation For Taxpayer & Consumer Rights, Requester And Appellant V. Patent Of Wisconsin Alumni Research Foundation, Patent Owner And Respondent. Appeal 2012-011693, Reexamination Control 95/000,154. Patent 7,029,913 Decision on Appeal
- GenomeWeb staff, July 03, 2013 Consumer Watchdog, PPF Seek Invalidation of WARF's Stem Cell Patent
- Antoinette Konski for Personalized Medicine Bulletin. February 3, 2014 U.S. Government and USPTO Urges Federal Circuit to Dismiss Stem Cell Appeal
- "Stem Cells - Overview". University of California San Francisco. Retrieved 19 December 2013.
- Matapurkar BG, Bhargave A, Dawson L, Sonal B (1999). "Regeneration of abdominal wall aponeurosis: New dimension in Marlex peritoneal sandwich repair of incisional hernia". World journal of surgery 23 (5): 446–450; discussion 450. doi:10.1007/PL00012326. PMID 10085391.
- Matapurkar BG, Gupta AK, Agarwal AK (1991). "A new technique of "Marlex-peritoneal sandwich" in the repair of large incisional hernias". World journal of surgery 15 (6): 768–770. doi:10.1007/BF01665314. PMID 1767543.
- Maingot, Rodney (1997). Abdominal Operations. ISBN 0838561063.
- Textbook of Gynaecology. JP Publications. 2010. pp. 620–625. ISBN 9350253690.
- Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM (1998). "Embryonic stem cell lines derived from human blastocysts". Science 282 (5391): 1145–7. Bibcode:1998Sci...282.1145T. doi:10.1126/science.282.5391.1145. PMID 9804556.
- Cibelli JB, Lanza RP, West MD, Ezzell C; Lanza; West; Ezzell (November 2001). "The first human cloned embryo". Scientific American 286: 44. Bibcode:2002SciAm.286a..44C. doi:10.1038/scientificamerican0102-44.
- Shostak S (2006). "(Re)defining stem cells". BioEssays 28 (3): 301–8. doi:10.1002/bies.20376. PMID 16479584.
- Keirstead HS, Nistor G, Bernal G, Totoiu M, Cloutier F, Sharp K, Steward O (2005). "Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury". The Journal of Neuroscience 25 (19): 4694–4705. doi:10.1523/JNEUROSCI.0311-05.2005. PMID 15888645.
- "Good news for alcoholics". Discover Magazine. March 2007. Retrieved 2010-02-28.
- Ross, ShãN (2006-10-31). "First liver grown from stem cells offers hope for transplant patients". Edinburgh: The Scotsman. Archived from the original on 2007-02-03.
- De Coppi P, Bartsch G, Siddiqui MM, Xu T, Santos CC, Perin L, Mostoslavsky G, Serre AC, Snyder EY, Yoo JJ, Furth ME, Soker S, Atala A (2007). "Isolation of amniotic stem cell lines with potential for therapy". Nat Biotechnol 25 (1): 100–6. doi:10.1038/nbt1274. PMID 17206138.
- Kaplan, Karen (8 January 2007). "Easy stem-cell source sparks interest: Researchers find amniotic fluid offers advantages". Boston Globe.
- Cyranoski D (2007). "Simple switch turns cells embryonic". Nature 447 (7145): 618–9. Bibcode:2007Natur.447..618C. doi:10.1038/447618a. PMID 17554270.
- Mitalipov SM, Zhou Q, Byrne JA, Ji WZ, Norgren RB, Wolf DP (2007). "Reprogramming following somatic cell nuclear transfer in primates is dependent upon nuclear remodeling". Hum Reprod 22 (8): 2232–42. doi:10.1093/humrep/dem136. PMID 17562675.
- "The Nobel prize in physiology or medicine 2007". Nobelprize.org. Retrieved 8 October 2007.
- Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007). "Induction of pluripotent stem cells from adult human fibroblasts by defined factors" (PDF). Cell 131 (5): 861–72. doi:10.1016/j.cell.2007.11.019. PMID 18035408.
- Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA (2007). "Induced pluripotent stem cell lines derived from human somatic cells". Science 318 (5858): 1917–20. Bibcode:2007Sci...318.1917Y. doi:10.1126/science.1151526. PMID 18029452.
- Chung Y, Klimanskaya I, Becker S, Li T, Maserati M, Lu SJ, Zdravkovic T, Ilic D, Genbacev O, Fisher S, Krtolica A, Lanza R (2008). "Human Embryonic Stem Cell Lines Generated without Embryo Destruction". Cell Stem Cell 2 (2): 113–117. doi:10.1016/j.stem.2007.12.013. PMID 18371431.
- French AJ, Adams CA, Anderson LS, Kitchen JR, Hughes MR, Wood SH (2008). "Development of human cloned blastocysts following somatic cell nuclear transfer (SCNT) with adult fibroblasts". Stem Cells Express 26 (2): 485–93. doi:10.1634/stemcells.2007-0252. PMID 18202077. Archived from the original on 2008-06-25.
- Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K, Chiba T, Yamanaka S (2008). "Generation of pluripotent stem cells from adult mouse liver and stomach cells". Science 321 (5889): 699–702. Bibcode:2008Sci...321..699A. doi:10.1126/science.1154884. PMID 18276851.
- Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D (2008). "Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells". Pain Physician 11 (3): 343–53. ISSN 1533-3159. PMID 18523506.
- Conrad S, Renninger M, Hennenlotter J, Wiesner T, Just L, Bonin M, Aicher W, Bühring HJ, Mattheus U, Mack A, Wagner HJ, Minger S, Matzkies M, Reppel M, Hescheler J, Sievert KD, Stenzl A, Skutella T (2008). "Generation of pluripotent stem cells from adult human testis". Nature 456 (7220): 344–9. Bibcode:2008Natur.456..344C. doi:10.1038/nature07404. PMID 18849962.
- Baker M (2008). "Embryonic-like stem cells from a single human hair". Nature Reports Stem Cells. doi:10.1038/stemcells.2008.142.
- Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hämäläinen R, Cowling R, Wang W, Liu P, Gertsenstein M, Kaji K, Sung HK, Nagy A (2009-03-01). "piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells". Nature 458 (7239): 766–70. Bibcode:2009Natur.458..766W. doi:10.1038/nature07863. PMID 19252478.
- "Canadians make stem cell breakthrough". March 1, 2009. Retrieved March 1, 2009.
- "Researchers find new method for turning adult cells into stem cells". Amherst Daily News. Canadian Press. 2009-01-03. Retrieved 2010-02-28.
- Sample, Ian (2009-03-01). "Scientists' stem cell breakthrough ends ethical dilemma". London: The Guardian. Retrieved 2009-03-03.
- Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K (2009). "Virus-free induction of pluripotency and subsequent excision of reprogramming factors". Nature 458 (7239): 771–5. Bibcode:2009Natur.458..771K. doi:10.1038/nature07864. PMC 2667910. PMID 19252477.
- Lee AS, Kahatapitiya P, Kramer B, Joya JE, Hook J, Liu R, Schevzov G, Alexander IE, McCowage G, Montarras D, Gunning PW, Hardeman EC (2009). "Methylguanine DNA methyltransferase-mediated drug resistance-based selective enrichment and engraftment of transplanted stem cells in skeletal muscle". Stem Cells 27 (5): 1098–1108. doi:10.1002/stem.28. PMID 19415780.
- Kim D, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, Ko S, Yang E, Cha KY, Lanza R, Kim KS (27 May 2009). "Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins". Cell Stem Cell 4 (6): 472–6. doi:10.1016/j.stem.2009.05.005. PMC 2705327. PMID 19481515. Lay summary. (cited in lay summary, not read)
- "First trial of embryonic stem cells in humans". BBC News. 2010-10-11.
- Ishikawa K, Toyama-Sorimachi N, Nakada K, Morimoto M, Imanishi H, Yoshizaki M, Sasawatari S, Niikura M, Takenaga K, Yonekawa H, Hayashi J (2010). "The innate immune system in host mice targets cells with allogenic mitochondrial DNA". J Exp Med. 207 (11): 2297–305. doi:10.1084/jem.20092296. PMC 2964578. PMID 20937705.
- Shtull-Trauring, Asaf (2011-09-06) Israeli scientist leads breakthrough stem cell research on endangered species
- Gordon, Serena (January 13, 2012). "USA Today". Novel stem cell treatment may hold promise for type 1 diabetes. Retrieved December 11, 2012.
- Teif VB, Vainshtein Y, Caudron-Herger M, Mallm JP, Marth C, Höfer T, Rippe K (2012). "Genome-wide nucleosome positioning during embryonic stem cell development.". Nat Struct Mol Biol. 19 (11): 1185–92. doi:10.1038/nsmb.2419. PMID 23085715.
- Hayashi K, Ogushi S, Kurimoto K, Shimamoto S, Ohta H, Saitou M (2012). "Offspring from oocytes derived from in vitro primordial germ cell-like cells in mice". Science 338 (6109): 971–5. doi:10.1126/science.1226889. PMID 23042295.
- Alok Jha, science correspondent (5 August 2013). "Anyone for a stem-cell burger?". The Guardian. Retrieved 2014-02-04.
- jobs (11 September 2013). "Stem cells created in living mice". Nature News & Comment. Nature.com. Retrieved 2014-02-04.
- "Edinburgh scientists use 3D printing to produce stem cells". BBC. 5 February 2013. Retrieved 5 February 2013.
- Kerry, Grens (29 January 2014). "New Method for Reprogramming Cells". scientist.com. Retrieved 2014-02-06.
- Bazian (30 January 2014). NHS Choices, ed. "Breakthrough in stem cell creation using acid bath". U.K. National Health Service. Retrieved 2014-02-06.
They put them in a weak acid solution (pH 5.7) for 30 minutes at 37°C, and then put them into petri dishes and grew them at normal pH.
- Cyranoski, David (18 March 2014). "Stem-cell method faces fresh questions". nature.com. Retrieved 2014-07-21.
- Cyranoski (17 June 2014). "Gene tests suggest acid-bath stem cells never existed". nature.com. Retrieved 2014-07-21.
|Wikimedia Commons has media related to Stem cells.|
- Stem Cell Basics Courtesy of the National Institutes of Health
- Nature Reports Stem Cells: Introductory material, research advances and debates concerning stem cell research.
- Understanding Stem Cells: A View of the Science and Issues from the National Academies
- Scientific American Magazine (June 2004 Issue) The Stem Cell Challenge
- Scientific American Magazine (July 2006 Issue) Stem Cells: The Real Culprits in Cancer?
- Ethics of Stem Cell Research entry by Andrew Siegel in the Stanford Encyclopedia of Philosophy
- Stem Cell Research at Johns Hopkins